Image de couverture de livre

From organs to algorithms: Redefining cancer classification in the age of artificial intelligence

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteur principal:	Sean Khozin
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Clinical and Translational Science
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

From data to decision: Scaling artificial intelligence with informatics for epilepsy management
par: Nishant Sinha, et autres
Publié: (2024)

How paediatric nursing can leverage the age of artificial intelligence to improve health outcomes and quality of care?
par: Pranay Bende
Publié: (2024)

Augmented intelligence in precision medicine: Transforming clinical decision‐making with AI/ML and/or quantitative systems pharmacology models
par: Sai Phanindra Venkatapurapu, et autres
Publié: (2024)

Radiomic‐based biomarkers: Transforming age and body composition metrics into personalized age‐informed indices
par: Radin Alikhani, et autres
Publié: (2024)

Regulation in the age of calamity: Changing the regulatory paradigm
par: Richard Hatchett, et autres
Publié: (2024)

Pharmacogenetics of tamoxifen in breast cancer patients of African descent: Lack of data
par: Bianca Kruger, et autres
Publié: (2024)

Pharmacogenomic studies of fertility outcomes in pediatric cancer survivors – A systematic review
par: Tayla Stenta, et autres
Publié: (2024)

Application of Human Plasma/Serum to Cell Culture In Vitro: A Translational Research Approach to Better Define Disease Mechanisms
par: Enis Cela, et autres
Publié: (2025)

Intestinal P‐gp activity is reduced in postmenopausal women under breast cancer therapy
par: Joao Paulo B. Ximenez, et autres
Publié: (2024)

Computational drug discovery pipelines identify NAMPT as a therapeutic target in neuroendocrine prostate cancer
par: Weijie Zhang, et autres
Publié: (2024)

Is there a possibility that P‐glycoprotein reduces reproductive toxicity in males but breast cancer resistance protein does not?
par: Zhiheng Yu, et autres
Publié: (2024)

Clinical and translational mode of single‐cell measurements: An artificial intelligent single cell
par: Xiangdong Wang, et autres
Publié: (2024)

Clinical and translational mode of single‐cell measurements: An artificial intelligent single‐cell
par: Xiangdong Wang, et autres
Publié: (2024)

Transforming precision medicine: The potential of the clinical artificial intelligent single‐cell framework
par: Christian Baumgartner, et autres
Publié: (2025)

Non‐targeted metabolomics for the identification of plasma metabolites associated with organic anion transporting polypeptide 1B1 function
par: Kreetta Hämäläinen, et autres
Publié: (2024)

Exploring the discrepancies between clinical trials and real‐world data: A small‐cell lung cancer study
par: Luca Marzano, et autres
Publié: (2024)

In vitro PK/PD modeling of tyrosine kinase inhibitors in non‐small cell lung cancer cell lines
par: Linda Wanika, et autres
Publié: (2024)

Real‐world implementation of DPYD and UGT1A1 pharmacogenetic testing in a community‐based cancer center
par: Megan Muldoon, et autres
Publié: (2024)

Effects of explainable artificial intelligence in neurology decision support
par: Grace Y. Gombolay, et autres
Publié: (2024)

From Precision to Personalized: Catalyzing AI ‐Enabled Innovation in Drug Development
par: Adarsh Subbaswamy, et autres
Publié: (2026)

Pharmacokinetics of SARS‐CoV‐2 RNA Polymerase Inhibitor Remdesivir in Participants With Moderate and Severe Hepatic Impairment
par: Sean Regan, et autres
Publié: (2025)

Translational findings support regimen selection for first‐in‐human study of ubamatamab (MUC16 × CD3 bispecific antibody) in patients with recurrent ovarian cancer
par: Min Zhu, et autres
Publié: (2024)

APOE Genotype and Statin Response: Evidence From the UK Biobank and All of Us Program
par: Innocent G. Asiimwe, et autres
Publié: (2025)

Authorship Order: Modest Proposals From a Retired Japanese Obstetrics‐Gynecology Professor
par: Shigeki Matsubara
Publié: (2025)

Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion‐driven non‐small cell lung cancer
par: Antoine Desilets, et autres
Publié: (2024)

Perspectives on Using Pharmacogenomics to Guide Tobacco Cessation: Survey Results From an American Indian Community
par: Madeline L. Wichman, et autres
Publié: (2025)

Reply to “Authorship Order: Modest Proposals From a Retired Japanese Obstetrics‐Gynecology Professor”
par: Hidenori Hashimoto, et autres
Publié: (2025)

From Lab to Clinic: Effect of Academia–Industry Collaboration Characteristics on Oncology Phase 1 Trial Entry
par: Wonseok Yang, et autres
Publié: (2025)

Pharmacokinetics of Bocidelpar, ASP0367, in Renal and Hepatic Impairment: Results From Two Phase 1 Studies
par: Megumi Iwai, et autres
Publié: (2025)

Repurposing Purine Analog Antivirals to Modulate Serum Uric Acid: Evidence From Real‐World Data
par: Joseph Magagnoli, et autres
Publié: (2026)

Insights From a User Experience‐Focused Virtual Study on the Feasibility and Challenges of Decentralized Clinical Trials
par: Yue Ma, et autres
Publié: (2025)

Impact of Efavirenz on Heme Protein Induction and Biomarkers: Insights From In Vitro Experiments and a Clinical Study
par: Leila Potzel, et autres
Publié: (2026)

Cross‐Reactive NSAID Hypersensitivity: Clinical Findings From Aspirin Provocation and Alternative Drug Challenge Testing
par: Young‐Il Koh, et autres
Publié: (2025)

Revolutionising acute aortic syndrome diagnosis: The role of artificial intelligence in non‐contrast computed tomography
par: Qiqi Wang, et autres
Publié: (2026)

Association of Vancomycin Plus Piperacillin‐Tazobactam With Acute Kidney Injury: Differentiating Pseudo‐Injury From True Nephrotoxicity
par: Congqin Chen, et autres
Publié: (2025)

Ethnic Bridging of Sepiapterin in Chinese and Korean Populations Based on Predictions From Genetic Polymorphism of Breast Cancer Resistance Protein
par: Lan Gao, et autres
Publié: (2026)

From Models to Medicines: A Narrative History and Regulatory Perspective on the Translational Impact of Model‐Informed Drug Development ( MIDD )
par: Issam Zineh
Publié: (2026)

Methods of Estimating Plasma Pharmacokinetics From Minimally Invasive, High Temporal Resolution Measurements of Interstitial Fluid Drug Concentrations
par: Murat K. Erdal, et autres
Publié: (2025)

High‐Frequency, At‐Home Monitoring of Drug Safety and Tolerability in Clinical Trials: Results From Studies of Fluvoxamine for COVID ‐19 Treatment
par: Eric J. Lenze, et autres
Publié: (2025)

Inter‐Ethnic Differences in the Efficacy and Safety of Tyrosine Kinase Inhibitors Used in Oncology: Insights From Phase 3 Clinical Trials
par: Nicki M. Kyriacou, et autres
Publié: (2025)